Cochrane Abstracts
Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes: Cochrane systematic review
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Ephedrine for Myasthenia Gravis, Neonatal Myasthenia and the Congenital Myasthenic Syndromes: Cochrane Systematic Review." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431817/all/Interventions_to_improve_adherence_to_lipid‐lowering_medication_Edited__no_change_to_conclusions_. Accessed 29 May 2023.
Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes: Cochrane systematic review. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431817/all/Interventions_to_improve_adherence_to_lipid‐lowering_medication_Edited__no_change_to_conclusions_. Accessed May 29, 2023.
Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes: Cochrane systematic review. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431817/all/Interventions_to_improve_adherence_to_lipid‐lowering_medication_Edited__no_change_to_conclusions_
Ephedrine for Myasthenia Gravis, Neonatal Myasthenia and the Congenital Myasthenic Syndromes: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. [cited 2023 May 29]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431817/all/Interventions_to_improve_adherence_to_lipid‐lowering_medication_Edited__no_change_to_conclusions_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes: Cochrane systematic review
ID - 431817
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431817/all/Interventions_to_improve_adherence_to_lipid‐lowering_medication_Edited__no_change_to_conclusions_
DB - Evidence Central
DP - Unbound Medicine
ER -
